<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03718884</url>
  </required_header>
  <id_info>
    <org_study_id>17117</org_study_id>
    <secondary_id>I6T-MC-AMBP</secondary_id>
    <nct_id>NCT03718884</nct_id>
  </id_info>
  <brief_title>A Study of Mirikizumab in Participants With Plaque Psoriasis</brief_title>
  <official_title>Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is known as a &quot;drug interaction study.&quot; The purpose is to learn how commonly used
      drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and
      their breakdown products get into the bloodstream after taking a &quot;cocktail&quot; (combination) of
      them before and after multiple doses of mirikizumab.

      The study will last about 23 weeks for each participant. Screening must be completed within 4
      weeks prior to study start.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2018</start_date>
  <completion_date type="Actual">October 28, 2019</completion_date>
  <primary_completion_date type="Actual">October 28, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Midazolam</measure>
    <time_frame>Period 1, Day 1 Predose through Period 2, Day 117</time_frame>
    <description>PK: Cmax of Midazolam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Cmax of Warfarin</measure>
    <time_frame>Period 1, Day 1 Predose through Period 2, Day 120</time_frame>
    <description>PK: Cmax of Warfarin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Cmax of Dextromethorphan</measure>
    <time_frame>Period 1, Day 1 Predose through Period 2, Day 119</time_frame>
    <description>PK: Cmax of Dextromethorphan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Cmax of Omepraxole</measure>
    <time_frame>Period 1, Day 1 Predose through Period 2, Day 118</time_frame>
    <description>PK: Cmax of Omepraxole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Cmax of Caffeine</measure>
    <time_frame>Period 1, Day 1 Predose through Period 2, Day 118</time_frame>
    <description>PK: Cmax of Caffeine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration Curve (AUC) Time Zero to Infinity (AUC [0-∞]) of Midazolam</measure>
    <time_frame>Period 1, Day 1 Predose through Period 2, Day 117</time_frame>
    <description>PK: AUC Time Zero to Infinity (AUC[0-∞]) of Midazolam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: AUC Time Zero to Infinity (AUC[0-∞]) of Warfarin</measure>
    <time_frame>Period 1, Day 1 Predose through Period 2, Day 120</time_frame>
    <description>PK: AUC Time Zero to Infinity (AUC[0-∞]) of Warfarin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: AUC Time Zero to Infinity (AUC[0-∞]) of Dextromethorphan</measure>
    <time_frame>Period 1, Day 1 Predose through Period 2, Day 119</time_frame>
    <description>PK: AUC Time Zero to Infinity (AUC[0-∞]) of Dextromethorphan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: AUC Time Zero to Infinity (AUC[0-∞]) of Omepraxole</measure>
    <time_frame>Period 1, Day 1 Predose through Period 2, Day 118</time_frame>
    <description>PK: AUC Time Zero to Infinity (AUC[0-∞]) of Omepraxole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: AUC Time Zero to Infinity (AUC[0-∞]) of Caffeine</measure>
    <time_frame>Period 1, Day 1 Predose through Period 2, Day 118</time_frame>
    <description>PK: AUC Time Zero to Infinity (AUC[0-∞]) of Caffeine</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Drug Cocktail</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug cocktail administered orally once in Period 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirikizumab + Drug Cocktail</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug cocktail administered orally once in Period 2 (day 116). Mirikizumab administered subcutaneously (SC) on multiple occasions in Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug Cocktail</intervention_name>
    <description>Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally</description>
    <arm_group_label>Drug Cocktail</arm_group_label>
    <arm_group_label>Mirikizumab + Drug Cocktail</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirikizumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Mirikizumab + Drug Cocktail</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females with chronic plaque psoriasis for at least 6 months who are
             candidates for systemic therapy or phototherapy

          -  Have greater than or equal to (≥) 10 percent body surface area (BSA) involvement at
             screening and first admission to the clinical site

        Exclusion Criteria:

          -  Pregnant or nursing (lactating)

          -  History of an ongoing, chronic or recurrent infectious disease, or evidence of
             tuberculosis infection

          -  Have major surgery within 8 weeks prior to first admission to the clinical site or
             during the study

          -  Have a history of lymphoma, leukemia, or any malignancy

          -  Require treatment with the cocktail drugs within 14 days prior to the first
             administration of the drug cocktail through the end of Week 12 assessments

          -  Have participated in any other study with mirikizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Point Clinical Trials Center</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>December 21, 2019</last_update_submitted>
  <last_update_submitted_qc>December 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

